Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Onco-Innovations Ltd. ( (TSE:ONCO) ) has shared an update.
Onco-Innovations Limited has appointed Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a renowned expert in organoboron chemistry and drug discovery, will provide strategic advice on the company’s research and development agenda, particularly in advancing their Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology. His appointment is expected to enhance the company’s efforts in developing precision therapies and strengthen its position in the oncology sector.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company is dedicated to pioneering research and innovative solutions for the prevention and treatment of cancer, and it holds an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 101,560
See more data about ONCO stock on TipRanks’ Stock Analysis page.